Bayer AG and Onyx Pharmaceuticals, Inc.'s Nexavar Score FDA Priority Review as Thyroid Cancer Drug

Bayer and Onyx Pharmaceuticals Announce FDA Priority Review Designation of NexavarA Supplemental New Drug Application for the Treatment of Radioactive Iodine-Refractory Differentiated Thyroid Cancer WHIPPANY, N.J. /PRNewswire/ -- Bayer HealthCare and Onyx Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted ... (more)

http://www.biospace.com/news_story.aspx?StoryID=306830&full=1